Contribution of β-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS)

Prospective analysis of the importance of the plasma levels of β-2 microglobulin (B2M) in 553 patients with myelodysplastic syndrome (MDS) found that B2M is an independent prognostic variable for survival with weighted significance second only to the karyotype. The incorporation of the B2M covariate...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2003-09, Vol.102 (5), p.1622-1625
Main Authors: Gatto, Simona, Ball, Greg, Onida, Francesco, Kantarjian, Hagop M., Estey, Elihu H., Beran, Miloslav
Format: Article
Language:English
Subjects:
beta 2-Microglobulin - blood
Biological and medical sciences
Female
Hematologic and hematopoietic diseases
Humans
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Male
Medical sciences
Middle Aged
Myelodysplastic Syndromes - blood
Myelodysplastic Syndromes - diagnosis
Myelodysplastic Syndromes - mortality
Predictive Value of Tests
Prognosis
Proportional Hazards Models
Prospective Studies
Risk Factors
Survival Analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prospective analysis of the importance of the plasma levels of β-2 microglobulin (B2M) in 553 patients with myelodysplastic syndrome (MDS) found that B2M is an independent prognostic variable for survival with weighted significance second only to the karyotype. The incorporation of the B2M covariate into risk assessment of MDS patients added significantly to the power of the IPSS to stratify MDS patients into risk categories. Our results further document that the 2 objectively measured covariates that display the highest power to predict survival, that is, karyotype and B2M, can alone be used for risk stratification. While the results must be verified in an independent and comparable population, our data strongly recommend routine measurement of B2M in patients with MDS.
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2002-10-3264